Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PIK3CA Mutated Advanced Solid Tumors”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04439175
What this trial is testing

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 70
Early research (Phase 1)WithdrawnNCT05472220
What this trial is testing

Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma

Who this might be right for
Solid Tumors, AdultPIK3CA Mutation-Related TumorsPIK3CA Mutation+5 more
Pamela Munster
Testing effectiveness (Phase 2)Looking for participantsNCT06993844
What this trial is testing

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsAdvanced Breast Cancer
Ensem Therapeutics 233
Early research (Phase 1)Not Yet RecruitingNCT07407504
What this trial is testing

GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.

Who this might be right for
Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated
Changchun GeneScience Pharmaceutical Co., Ltd. 186
Early research (Phase 1)Study completedNCT05300048
What this trial is testing

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Who this might be right for
Advanced Solid TumorPIK3CA MutationPTEN Loss of Function Mutation
Faeth Therapeutics 34
Early research (Phase 1)Study completedNCT01473095
What this trial is testing

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

Who this might be right for
Solid TumorMalignant LymphomaTumor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 120
Early research (Phase 1)Study completedNCT01219699
What this trial is testing

BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Who this might be right for
Advanced Solid Tumors With an Alteration of the PIK3CA GeneEstrogen Receptor Positive Breast Cancer
Novartis Pharmaceuticals 221
Testing effectiveness (Phase 2)Looking for participantsNCT05768139
What this trial is testing

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Who this might be right for
Breast CancerSolid Tumors, Adult
Eli Lilly and Company 720
Testing effectiveness (Phase 2)WithdrawnNCT01501604
What this trial is testing

BKM120 in Cancers With PIK3CA Activating Mutations

Who this might be right for
Lung CancerBreast CancerColorectal Cancer+2 more
Massachusetts General Hospital
Early research (Phase 1)Study completedNCT02260661
What this trial is testing

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

Who this might be right for
Advanced Solid MalignanciesBreast Cancer - ER+, HER2 -Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
AstraZeneca 20
Early research (Phase 1)UnknownNCT04631835
What this trial is testing

Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 54
Early research (Phase 1)Looking for participantsNCT05216432
What this trial is testing

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Who this might be right for
PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc. 930
Testing effectiveness (Phase 2)Study completedNCT06132932
What this trial is testing

WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations

Who this might be right for
PIK3CA Mutation-Related Tumors
Shanghai Jiatan Pharmatech Co., Ltd 38
Early research (Phase 1)Study completedNCT01226316
What this trial is testing

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Who this might be right for
Advanced Solid MalignancySafety and TolerabilityPharmacokinetics+11 more
AstraZeneca 285
Testing effectiveness (Phase 2)Ended earlyNCT01708161
What this trial is testing

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

Who this might be right for
PIK3CA Mutated Advanced Solid TumorsPIK3CA Amplified Advanced Solid Tumors
Novartis Pharmaceuticals 47
Early research (Phase 1)Study completedNCT05759949
What this trial is testing

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Who this might be right for
PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+5 more
Relay Therapeutics, Inc. 41
Early research (Phase 1)Active Not RecruitingNCT05307705
What this trial is testing

LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

Who this might be right for
Breast Cancer
Eli Lilly and Company 193